Related Experiment Video
Updated: Jul 6, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Delivery of whole tumor lysate into dendritic cells for cancer vaccination
Linda N Liu1, Rama Shivakumar, Cornell Allen
1MaxCyte Inc, Gaithersburg, MD, USA.
Abstract:
Results from multiple human studies have continued to spur the development of dendritic cells (DCs) as therapeutic vaccines for the treatment of cancer, chronic viral infections, and autoimmune diseases. The antigen-specific activity of DCs is dependent on the ability of the DCs to take up and process tumor-associated antigens for presentation to the immune system. Although immature DCs have been shown to naturally take up tumor-associated antigens by phagocytosis, approaches that significantly affect antigen delivery need further evaluation, especially if such methodologies can be demonstrated to result in the elicitation of more robust and comprehensive immune responses. We have developed a rapid, robust, scalable, and regulatory-compliant process for loading DCs with whole tumor lysate. The use of whole tumor lysate facilitates the generation of a more robust immune response targeting multiple unique antigenic determinants in patient's tumors and likely reduces the tumor's potential of immune escape. We demonstrate that DCs electroloaded with tumor lysate elicit significantly stronger antitumor responses both in a tumor challenge model and in a therapeutic vaccination model for preexisting metastasic disease. These effects are observed in a processing scheme that requires 20- to 40-fold lower amounts of tumor lysate when compared with the standard coincubation/coculture methods employed in loading DCs.
Insights
Dendritic cells (DCs) loaded with whole tumor lysate via electroloading generate stronger antitumor responses. This method is efficient, requiring less tumor material than traditional approaches for cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Dendritic cells (DCs) are crucial for initiating immune responses and are explored as therapeutic vaccines.
- Effective antigen presentation by DCs is key for their therapeutic activity.
- Current methods for loading DCs with antigens need optimization for enhanced immune responses.
Purpose of the Study:
- To develop an efficient and scalable method for loading DCs with whole tumor lysate.
- To evaluate the immunogenicity and efficacy of electroloaded DCs in preclinical cancer models.
Main Methods:
- Development of a rapid, robust, scalable, and regulatory-compliant process for DC loading using whole tumor lysate.
- Utilizing electroporation for efficient antigen delivery into DCs.
- Assessment of antitumor responses in tumor challenge and therapeutic vaccination models.
Main Results:
- Electroloading DCs with whole tumor lysate generates significantly stronger antitumor responses compared to standard methods.
- This approach targets multiple tumor antigens, potentially reducing immune escape.
- The method requires 20- to 40-fold less tumor lysate than coincubation/coculture techniques.
Conclusions:
- Electroloading DCs with whole tumor lysate is a highly effective strategy for enhancing antitumor immunity.
- This optimized antigen delivery method offers a promising avenue for cancer immunotherapy development.
- The reduced material requirement makes this approach more practical and potentially cost-effective.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy